Trial Profile
Phase II study of intravenous Vinorelbine (Navelbine) and Capecitabine (Xeloda) in patients with advanced breast cancer, assessing efficacy and toxicity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms NavXel
- 14 May 2009 New trial record